ClinicalTrials.gg
Not yet recruitingNCT07572591Updated May 7, 2026

Ultrasound for Peripheral Nerve Modulation

An interventional study of Ultrasound and Sham (No Treatment) in Neuropathic Pain and Chronic Pain, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Stanford University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Neuralgia by Stanford University — 6 open to participants now, 6 under way, 2 of them phase 3. Neuralgia · Stanford University.

Planned enrollment
7th of 12
90 · median 93
Started
2026
with 1 other
No phase
5 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Neuralgia by Stanford University, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

6 of the 12 studies in Neuralgia by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Neuralgia by Stanford University, or all of them as a file.
02

Study summary

This study evaluates an ultrasound device designed to reduce pain by targeting peripheral nerves without surgery or medication. The device is placed on the skin over the area of pain and delivers controlled ultrasound stimulation.

Adults with nerve-related pain will participate in a single study visit that includes stimulation sessions and pain assessments.

The goal of this study is to determine whether non-invasive ultrasound can safely and effectively reduce pain and to assess whether this approach is practical for future clinical use.

03

Conditions studied

  • Neuropathic Pain
  • Chronic Pain

Keywords

  • ultrasound
  • modulation
  • peripheral nerve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stated willingness to comply with all study procedures and availability for the duration of the study
  2. Persons aged 18 and older.
  3. In good general health as evidenced by medical history
  4. Chronic pain located in the distribution of any of the target nerves of interest, including the occipital, suprascapular, median, femoral/leg, stellate ganglion/vagus nerves, neuroma, or amputees.

Exclusion criteria

Exclusion Criteria:

  • Patients with compromised skin integrity for whom device placement would result in increased risk of harm (such as those with extensive burns, active dermatologic conditions, or wounds that would prevent safe device placement)
  • Pregnant patients, as the devices have not been validated in this population
  • Additionally, the treating clinician may exclude any patient if they determine that study participation would be inappropriate for the patient's clinical condition.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Sham comparator
    Sham

    Participants undergo sham ultrasound stimulation that replicates all procedural aspects of active treatment without delivery of therapeutic acoustic energy.

    Device: Sham (No Treatment)

  • Experimental
    Ultrasound modulation

    Participants receive ultrasound stimulation at predefined parameters to evaluate neuromodulatory effects on the target peripheral nerve.

    Device: Ultrasound

Interventions

  • DeviceUltrasound

    Non-invasive focused ultrasound stimulation is applied to a target peripheral nerve.

  • DeviceSham (No Treatment)

    Sham stimulation replicates all procedural aspects of active ultrasound neuromodulation, including device placement and operation, without delivery of therapeutic acoustic energy. This condition serves as a control to account for placebo and procedural effects.

06

What researchers measure

Primary outcomes

  1. Incidence of Device-Related Adverse Events

    Assessment of the number and severity of device- and procedure-related adverse events associated with focused ultrasound neuromodulation. Events will be graded according to standard clinical criteria, including pain, skin irritation, thermal effects, or neurologic symptoms.

    Time frame: From treatment to the next day (up to two days)

Secondary outcomes

  1. Change in Numerical Pain Rating Scale

    Participant-reported tolerability assessed using a numerical pain rating scale (e.g., discomfort or pain score during stimulation). The scale ranges from 1 (no pain) through 10 (worst pain).

    Time frame: During, immediately after each stimulation block, and one day after the treatment (up to two days)

07

Study locations

1 site
08

References and documents

Publications

  • McCune EP, Blackman SG, Kamimura HAS, Bendau EV, Sachs TD, Kim S, Lee SA, Winfree CJ, Konofagou EE. Displacement-Guided Focused Ultrasound of the Median Nerve Modulates Somatosensory Evoked Potentials in Humans. IEEE Trans Biomed Eng. 2026 Mar;73(3):1255-1267. doi: 10.1109/TBME.2025.3602291. PubMed 40857198 ↗
  • Ilfeld BM, Cao KN, Branson R, Bloom P. Ultrasound Neuromodulation (Low-Intensity Focused Ultrasound) to Treat Knee Osteoarthritis Pain: A Randomized, Observer- and Participant-Masked, Sham-Controlled, Human-Subjects Pilot Study. J Ultrasound Med. 2025 Sep;44(9):1713-1721. doi: 10.1002/jum.16706. Epub 2025 Apr 17. PubMed 40241493 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared at this stage due to the early feasibility nature of the study and the small sample size, which may increase the risk of participant re-identification. De-identified, aggregated results will be reported in publications and presentations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 7, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07572591
Responsible party
Sheng Xu (Professor in the Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University) — Principal investigator
First posted
May 7, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 7, 2026

Study contacts

Tom Park, PhD
Contact
tompark@stanford.edu
Sheng Xu, PhD
study director · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion